Dasiglucagon
Zegalogue (dasiglucagon) is an unknown pharmaceutical. Dasiglucagon was first approved as Zegalogue on 2021-03-22. It is used to treat hypoglycemia in the USA.
Download report
Favorite
FDA Novel Drug Approvals 2021
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Zegalogue
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
zegalogue | New Drug Application | 2023-01-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hypoglycemia | HP_0001943 | D007003 | E16.2 |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
DASIGLUCAGON HYDROCHLORIDE, ZEGALOGUE, ZEALAND PHARMA | |||
2026-03-22 | NCE | ||
DASIGLUCAGON HYDROCHLORIDE, ZEGALOGUE (AUTOINJECTOR), ZEALAND PHARMA | |||
2026-03-22 | NCE |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Dasiglucagon Hydrochloride, Zegalogue, Zealand Pharma | |||
10442847 | 2035-02-03 | DS, DP |
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypoglycemia | D007003 | HP_0001943 | E16.2 | 3 | 6 | 6 | — | — | 15 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 6 | 5 | — | — | 10 |
Congenital hyperinsulinism | D044903 | — | 3 | 3 | — | — | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glucose metabolism disorders | D044882 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | DASIGLUCAGON |
INN | dasiglucagon |
Description | Dasiglucagon, sold under the brand name Zegalogue, is a medication used to treat severe hypoglycemia in people with diabetes.
|
Classification | Small molecule |
Drug class | synthetic glucagon analogs |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)[C@@H](C)O |
Identifiers
PDB | — |
CAS-ID | 1544300-84-6 |
RxCUI | — |
ChEMBL ID | CHEMBL4297741 |
ChEBI ID | — |
PubChem CID | 126961379 |
DrugBank | DB15226 |
UNII ID | AD4J2O47FQ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 82 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
26,924 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more